Benralizumab

(Fasenra)

Benralizumab

Drug updated on 11/13/2023

Dosage FormInjection (subcutaneous; 30 mg/mL)
Drug ClassInterleukin-5 receptor alpha-directed cytolytic monoclonal antibodies
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

Product Monograph / Prescribing Information

Document TitleYearSource
Fasenra (benralizumab) Prescribing Information .2021AstraZeneca

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.2023The Journal of allergy and clinical immunology.
Anti‐IL‐5 therapies for asthma. 2022Cochrane Database of Systematic Reviews
Comparative efficacy and safety of tezepelumab and other biologics in patients with inadequately controlled asthma according to thresholds of type 2 inflammatory biomarkers: a systematic review and network meta-analysis.2022Cells
Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis. 2022Clinical and experimental allergy
Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis. 2022The Journal of allergy and clinical immunology
Comparative efficacy and safety of dupilumab and benralizumab in patients with inadequately controlled asthma: a systematic review. 2020International Journal of Molecular Sciences
Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: a systematic review. 2020Clinical and Experimental Allergy
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma. 2020Allergy
Clinical review report: benralizumab (Fasenra). 2019CADTH
Adverse events of benralizumab in moderate to severe eosinophilic asthma: a meta-analysis. 2019Medicine
Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis. 2019BMC Respiratory Journal
Australian public assessment report for benralizumab. 2019Australian Government: Department of Health
Biologic therapies for treatment of asthma associated with type 2 inflammation: effectiveness, value, and value-based price benchmarks. 2018ICER
Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review. 2018European Respiratory Journal

Clinical Practice Guidelines